Results 1 to 10 of about 38,769 (305)
Tolerability of SGLT2 inhibitors in patients with Fabry disease: An observational study [PDF]
American Heart Journal PlusCardiac involvement of Fabry disease (FD) includes heart failure (HF) treated according to general guideline recommendations. The retrospective study investigates HF medication in FD focusing on sodium glucose cotransporter 2 (SGLT2) inhibitors.
Isabel Mattig +7 more
doaj +2 more sources
SGLT2 Inhibitors and Their Antiarrhythmic Properties [PDF]
International Journal of Molecular Sciences, 2022 Sodium-glucose cotransporter 2 (SGLT2) inhibitors are gaining ground as standard therapy for heart failure with a class-I recommendation in the recently updated heart failure guidelines from the European Society of Cardiology. Different gliflozins have shown impressive beneficial effects in patients with and without diabetes mellitus type 2, especially
Ewald Koleśnik, , Ursula Rohrer
exaly +3 more sources
Benefits of SGLT2 inhibitors in arrhythmias
Frontiers in Cardiovascular Medicine, 2022 Some studies have shown that sodium-glucose cotransporter (SGLT) 2 inhibitors can definitively attenuate the occurrence of cardiovascular diseases such as heart failure (HF), dilated cardiomyopathy (DCM), and myocardial infarction.
Jinghan Gao +6 more
doaj +3 more sources
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
Frontiers in Pharmacology, 2022 Sodium-glucose cotransporter 2 (SGLT2) inhibitors exert hypoglycemic and diuretic effects by inhibiting the absorption of sodium and glucose from the proximal tubule.
Jun Tang +9 more
doaj +1 more source
Diabetes & Vascular Disease Research, 2021 There are no relevant meta-analyses that have assessed the safety of the sodium-glucose transporter 2 (SGLT2) inhibitors in different chronic diseases. We aimed at evaluating the safety of four SGLT2 inhibitors in three chronic diseases by meta-analysis ...
Mei Qiu +3 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 BackgroundSodium-glucose co-transporter 2 (SGLT2) inhibitors has been shown with cardiovascular benefit in type 2 diabetes mellitus (T2DM) patients. However, its osmotic diuresis still concern physicians who may look for possible electrolyte imbalance ...
Victor Chien-Chia Wu +15 more
doaj +1 more source
Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
Frontiers in Cardiovascular Medicine, 2022 Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been incorporated as guideline-directed medical therapy for heart failure with reduced ejection fraction.
Ting-Wei Kao +5 more
doaj +1 more source
Neuroprotective Effect of SGLT2 Inhibitors [PDF]
Molecules, 2021 Patients with diabetes are at higher risk of cardiovascular diseases and cognitive impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Sotagliflozin) are newer hypoglycemic agents with many pleiotropic effects. In this review, we discuss their neuroprotective potential.
Agnieszka Pawlos +3 more
openaire +3 more sources
SGLT2 Inhibitors: Physiology and Pharmacology [PDF]
Kidney360, 2021 SGLTs are sodium glucose transporters found on the luminal membrane of the proximal tubule, where they reabsorb some 180 g (1 mol) of glucose from the glomerular filtrate each day. The natural glucoside phlorizin completely blocks glucose reabsorption. Oral SGLT2 inhibitors are rapidly absorbed into the blood stream, where theyremain in the circulation
openaire +2 more sources
Frontiers in Pharmacology, 2023 Background: Sodium–glucose cotransporter-2 (SGLT2) inhibitors have proven to be effective in improving glycemic control in patients with type 2 diabetes mellitus (T2DM). However, the risk of diabetic ketoacidosis (DKA) in patients remains unclear.
Shiwen Yang +9 more
doaj +1 more source